{"id":39073,"date":"2020-09-08T04:27:45","date_gmt":"2020-09-08T04:27:45","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=39073"},"modified":"2020-09-08T04:27:45","modified_gmt":"2020-09-08T04:27:45","slug":"recombinant-dna-advisory-committee-rac","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/","title":{"rendered":"Recombinant DNA advisory committee (RAC)"},"content":{"rendered":"

The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government’s regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the “human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized.”<\/p>\n

\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government’s regulatory process for recombinant DNA research and product […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-39073","post","type-post","status-publish","format-standard","hentry","category-r"],"yoast_head":"\nRecombinant DNA advisory committee (RAC) - Definition of Recombinant DNA advisory committee (RAC)<\/title>\n<meta name=\"description\" content=\"The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government's regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the "human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized."\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recombinant DNA advisory committee (RAC) - Definition of Recombinant DNA advisory committee (RAC)\" \/>\n<meta property=\"og:description\" content=\"The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government's regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the "human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-08T04:27:45+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/\",\"name\":\"Recombinant DNA advisory committee (RAC) - Definition of Recombinant DNA advisory committee (RAC)\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-09-08T04:27:45+00:00\",\"dateModified\":\"2020-09-08T04:27:45+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government's regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the \\\"human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized.\\\"\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recombinant DNA advisory committee (RAC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recombinant DNA advisory committee (RAC) - Definition of Recombinant DNA advisory committee (RAC)","description":"The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government's regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the \"human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized.\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/","og_locale":"en_US","og_type":"article","og_title":"Recombinant DNA advisory committee (RAC) - Definition of Recombinant DNA advisory committee (RAC)","og_description":"The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government's regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the \"human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized.\"","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/","og_site_name":"Glossary","article_published_time":"2020-09-08T04:27:45+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/","name":"Recombinant DNA advisory committee (RAC) - Definition of Recombinant DNA advisory committee (RAC)","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-09-08T04:27:45+00:00","dateModified":"2020-09-08T04:27:45+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"The former standing U.S. national committee set up in 1974 by the National Institutes of Health (NIH) to advise the NIH director on matters regarding policy and safety issues of recombinant DNA research and development. Over time, it had evolved to become part of the American government's regulatory process for recombinant DNA research and product approval. The RAC was terminated by the director ofthe NIH in 1 996 because the \"human health and environmental safety concerns expressed at the inception (of genetic engineering\/biotechnology) had not materialized.\"","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/recombinant-dna-advisory-committee-rac\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Recombinant DNA advisory committee (RAC)"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/39073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=39073"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/39073\/revisions"}],"predecessor-version":[{"id":39074,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/39073\/revisions\/39074"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=39073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=39073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=39073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}